跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

06863

Sigma-Aldrich

甘氨酰去氧胆酸

≥96.0% (TLC)

别名:

N-(3α,7β-二羟基-5β-cholan-24-oyl）甘氨酸, N-[(3α, 5β, 7β）-3,7-二羟基-24-氧代胆甾烷-24-基 ] 甘氨酸, GUDCA, 乌索脱氧胆基甘氨酸, 甘氨酰脱氧胆酸

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C26H43NO5
CAS号:
64480-66-6
分子量:
449.62
MDL编号:
MFCD00137427
UNSPSC代码:
12161900
PubChem化学物质编号:
329748294
NACRES:
NA.25

生物来源

synthetic

质量水平

100

方案

≥96.0% (TLC)

表单

powder

官能团

carboxylic acid

SMILES字符串

[H][C@@]12[C@]([C@](CC[C@@H](O)C3)(C)[C@]3([H])C[C@@H]2O)([H])CC[C@@]4(C)[C@@]1([H])CC[C@]4([H])[C@]([H])(C)CCC(NCC(O)=O)=O
[H][C@@]12[C@]([C@](CC[C@@H](O)C3)(C)[C@]3([H])C[C@@H]2O)([H])CC[C@@]4(C)[C@@]1([H])CC[C@]4([H])[C@]([H])(C)CCC(NCC(O)=O)=O

InChI

1S/C26H43NO5/c1-15(4-7-22(30)27-14-23(31)32)18-5-6-19-24-20(9-11-26(18,19)3)25(2)10-8-17(28)12-16(25)13-21(24)29/h15-21,24,28-29H,4-14H2,1-3H3,(H,27,30)(H,31,32)/t15-,16+,17-,18-,19+,20+,21+,24+,25+,26-/m1/s1

InChI key

GHCZAUBVMUEKKP-XROMFQGDSA-N

相关类别

应用


  • 甘氨熊去氧胆酸通过抑制血小板中二酰基甘油激酶活性来缓解动脉血栓形成。: 重点介绍了甘氨熊去氧胆酸通过抑制血小板中二酰基甘油激酶活性来缓解动脉血栓形成的治疗潜力（Yang et al., 2024）。

生化/生理作用

来源于酰基甘氨酸的次级胆汁酸。据报道甘氨脱氧胆酸 (GUDCA) 具有细胞保护和抗炎作用。

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
BCCK3112
BCCJ6579
BCCD4705
BCCB9011
BCCB9976

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Sandra L Silva et al.
Neuropharmacology, 62(7), 2398-2408 (2012-03-01)
Neuronal oxidative damage and cell death by unconjugated bilirubin (UCB) showed to be mediated by overstimulation of glutamate receptors and nitric oxide (NO) production, which was abrogated by the bile acid glycoursodeoxycholic acid (GUDCA). Microglia, a crucial mediator of CNS
Kazuya Maeda et al.
Molecular pharmaceutics, 3(1), 70-77 (2006-05-12)
Ursodeoxycholate (UDCA) is widely used for the treatment of cholestatic liver disease. After oral administration, UDCA is absorbed, taken up efficiently by hepatocytes, and conjugated mainly with glycine to form glycoursodeoxycholate (GUDC) or partly with taurine to form tauroursodeoxycholate (TUDC)
Jingyu Yan et al.
Scientific reports, 7(1), 4211-4211 (2017-06-25)
Cholestasis is a clinical disorder defined as an impairment of bile flow, and that leads to toxic bile acid (BA) accumulation in hepatocytes. Here, we investigated the hepatoprotective effect of Yinchenhaotang (YCHT), a well-known formulae for the treatment of jaundice
A Roda et al.
Pharmaceutical research, 11(5), 642-647 (1994-05-01)
A new enteric-coated formulation of sodium ursodeoxycholate was prepared and administered to man. The barrier film disintegrates and releases the drug only at pH > or = 5.5. The sodium salt of glycoursodeoxycholate was also prepared and encapsulated like ursodeoxycholate.
A Roda et al.
The Journal of biological chemistry, 258(10), 6362-6370 (1983-05-25)
The relationship between chemical structure and the concentration at which self-association occurs in water or in 0.15 M Na+ ion was examined for more than 50 bile salts and bile salt analogues varying in substituents on the steroid nucleus or
查看所有相关文献

实验方案

HPLC Separation of Bile Acids with Ascentis Express C18

Investigate bile acid roles in gut hormone profiles and glycemic control, vital for clinical labs exploring potential mechanisms.

相关内容

Bile Acids Kit for LC-MS

Bile Acids (BA) are synthesized in the liver and play important roles in cholesterol homeostasis, absorption of vitamins and lipids, and various key metabolic processes.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门